Application Value of Soluble Receptor of Advanced Glycation End Products in the Diagnostic and Prognostic Assessment of Patients with Acute Respiratory Distress Syndrome

Objective To discuss the application value about soluble receptor for advanced glycation end products(sRAGE) in the diagnostic and prognostic assessment of patients with acute respiratory distress syndrome(ARDS) in the intensive care unit(ICU). Methods 60 ARDS patients admitted to the First Affiliated Hospital of Liaoning Medical University from March 2012 to March 2013 were selected. The patients were divided into mild group(23 cases),moderate group(23 cases) and severe group(14 cases) based on oxygenation index(PaO2/FiO2),and were divided into death group(18 cases) and survival group(42 cases). Another 60 patients admitted to ICU during the same period were selected as non-ARDS group. ELISA method was used to detect sRAGE level,and the PaO2/FiO2 was also recorded. Results Compared with the non-ARDS group,the ARDS group had higher sRAGE level and lower PaO2/FiO2(P 0.05). The sRAGE level and PaO2/FiO2 of ARDS patients with different severities showed statistically significant differences(P 0. 05). As for the sRAGE level,the moderate group and severe group were higher than the mild group,and the severe group was higher than the moderate group and mild group,but the PaO2/FiO2 was just the opposite(P 0. 05). The sRAGE level in the death group was higher than the survival group,but the PaO2/FiO2 was lower(P 0. 05). Linear correlation analysis showed that the sRAGE level in ARDS patients was negatively correlated with PaO2/FiO2(r =-0.949,P =0.000 2). Conclusion Plasma sRAGE is helpful in the diagnosis and prognosis prediction in the ICU. It can be used as a prognostic biochemical marker for ARDS. It may be also helpful in the diagnosis of ARDS,but needs further study to verify.